Frequent genomic aberrations of CDK4/6 in rhabdomyosarcoma, osteosarcoma, and other pediatric tumors were documented by means of the target actionability review (TAR) methodology to assess data on CDK4/6 as a therapeutic target in pediatric solid tumors. Here, CDK4 is linked to osteosarcoma.